Your session is about to expire
← Back to Search
CombinationProduct
ctDNA Testing for Oropharyngeal Cancer
Phase 2
Recruiting
Led By Linda Chen, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
A minimum of one of the following pathologic criteria (Arm B): - Microscopic positive margin - Extracapsular extension
ECOG 0-2
Must not have
Severe, active co-morbidity defined as follows: - Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months - Transmural myocardial infarction within the last 6 months - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration - Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization within 30 days of registration - Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects - Lack of ability to understand and willingness to sign a written informed consent and complete questionnaires.
Metastatic disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a blood test to detect tiny pieces of HPV DNA in people with throat cancer who have had surgery. The goal is to see if this test can help decide if and when they need more treatment like radiation or chemotherapy.
Who is the study for?
This trial is for adults with HPV-16 related oropharyngeal cancer who've had surgery to remove the tumor and show no signs of cancer in post-op imaging. They must have certain blood markers, good organ function, and be able to consent. People with metastatic disease, non-HPV16 cancers, prior chemo for this cancer, severe health issues like recent heart failure or infections can't join.
What is being tested?
The study tests if monitoring cell-free tumor DNA (ctDNA) levels can guide treatment timing after surgery. Arm A explores delaying radiation therapy until ctDNA is detectable again. Arm B checks if patients normally needing longer chemoradiation could receive a shorter 3-week course based on their ctDNA levels.
What are the potential side effects?
Potential side effects are not explicitly listed but may include typical reactions from radiation therapy such as skin irritation, fatigue, dry mouth/throat issues; and from chemotherapy like nausea/vomiting, low blood counts leading to increased infection risk.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My cancer has spread beyond its original location or has cells at the surgery margin.
Select...
I am able to care for myself and move around.
Select...
I am 18 years old or older.
Select...
I've undergone specific tests and procedures to find the origin of my cancer, followed by surgery to remove lymph nodes in my neck.
Select...
My cancer stage or features meet specific criteria for a study group.
Select...
My test shows HPV DNA in my blood above 50 copies/mL.
Select...
My surgery removed all visible cancer, and none was seen on scans after.
Select...
My cancer is HPV-16 positive in the throat or head and neck, confirmed by a specific test.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My cancer has spread to other parts of my body.
Select...
I have cancer in areas other than the oropharynx.
Select...
My HPV ctDNA levels are 50 copies/mL or lower before surgery.
Select...
My HPV type is not HPV16.
Select...
I have received chemotherapy for my current cancer.
Select...
I have had radiation therapy on my head or neck before.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Pathologically confirmed progression free survival
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Screening, active surveillance, and treatment (Arm A)Experimental Treatment6 Interventions
Participants who meet criteria for the treatment phase (a post-operative HPV ctDNA which rose from initial undetectable to meet HPV16 ctDNA criteria and have no clinical or radiographic evidence of gross disease) will undergo delayed standard of care adjuvant radiation (50-60 Gy administered in 1.8-2 Gy fractions) based on the patient's initial pathology. Treatment will be initiated within 4 weeks of a NavDx result. Subjects will undergo FDG PET/CT simulation and standard radiation treatment planning and this FDG PET/CT will also be utilized to rule out distant metastases. Diagnostic FDG PET/CT fusion is also allowed for treatment planning and to rule out distant metastases. Non-therapeutic assessments will be completed.
Group II: Screening and deescalated treatment (Arm B)Experimental Treatment6 Interventions
Participants who meet criteria for the de-escalated treatment phase (Arm B) will undergo adjuvant radiation (30 Gy administered in 2 Gy fractions) with concurrent chemotherapy.
They will undergo FDG PET/CT simulation and standard radiation treatment planning and this FDG PET/CT will also be utilized to rule out distant metastases. Diagnostic FDG PET/CT fusion is also allowed for treatment planning and to rule out distant metastases. Non-therapeutic assessments will be completed and the Study calendar.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Oropharyngeal Carcinoma (OPC) include radiation therapy (RT), chemoradiation therapy (CRT), and emerging biomarker-based monitoring like HPV ctDNA. RT uses high-energy radiation to kill cancer cells by damaging their DNA, while CRT combines RT with chemotherapy agents like cisplatin to enhance the cancer-killing effects.
The use of HPV ctDNA as a biomarker allows for the detection of minimal residual disease and early relapse, potentially guiding the timing and intensity of treatment. These mechanisms are crucial for OPC patients as they offer targeted, effective treatment options and personalized monitoring, which can improve outcomes and reduce unnecessary treatment-related toxicity.
Tracking the Molecular Fingerprint of Head and Neck Cancer for Recurrence Detection in Liquid Biopsies.Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma.[Oral cavity cancers among young people: Clinical results and prognostic analysis].
Tracking the Molecular Fingerprint of Head and Neck Cancer for Recurrence Detection in Liquid Biopsies.Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma.[Oral cavity cancers among young people: Clinical results and prognostic analysis].
Find a Location
Who is running the clinical trial?
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,979 Previous Clinical Trials
599,808 Total Patients Enrolled
1 Trials studying Oropharyngeal Carcinoma
121 Patients Enrolled for Oropharyngeal Carcinoma
Linda Chen, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My cancer is HPV-16 positive in the throat or head and neck area.My post-surgery HPV cancer tests were negative twice.My cancer has spread beyond its original location or has cells at the surgery margin.My cancer has spread to other parts of my body.I have cancer in areas other than the oropharynx.My HPV ctDNA levels are 50 copies/mL or lower before surgery.I am able to care for myself and move around.My HPV type is not HPV16.I am 18 years old or older.I've undergone specific tests and procedures to find the origin of my cancer, followed by surgery to remove lymph nodes in my neck.I have received chemotherapy for my current cancer.My cancer stage or features meet specific criteria for a study group.I have been cancer-free for 3 years, except for non-dangerous skin cancers.I had my surgery at a different hospital, but it might still be okay.My test shows HPV DNA in my blood above 50 copies/mL.My surgery removed all visible cancer, and none was seen on scans after.My post-surgery HPV cancer tests were undetectable twice.I have had radiation therapy on my head or neck before.My cancer is HPV-16 positive in the throat or head and neck, confirmed by a specific test.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Research Study Groups:
This trial has the following groups:- Group 1: Screening and deescalated treatment (Arm B)
- Group 2: Screening, active surveillance, and treatment (Arm A)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.